Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 16Multiple Myeloma 13Neoplasms 12Colorectal Neoplasms 8Neoplasms, Plasma Cell 7Myelodysplastic Syndromes 7Leukemia, Myeloid, Acute 6Glioblastoma 5Sarcoma 4Prostatic Neoplasms 4Leukemia, Myelomonocytic, Chronic 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Skin Neoplasms 3Inflammation 3Colonic Neoplasms 3Stomatitis 2Stomach Neoplasms 2Recurrence 2Primary Myelofibrosis 2Ovarian Neoplasms 2Neoplasms by Site 2Myofibroma 2Myeloproliferative Disorders 2Lymphoma 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Glioma 2Frailty 2

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Ascorbic Acid × Clear all
NCT04150042 2026-01-29

SHARON

General Oncology, Inc.

Phase 1 Recruiting
24 enrolled
BreastGastrointestinal

Breast Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Oncotherapeutics

Phase 1/2 Completed
45 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡